Spring til...

  • Hovedindhold
  • Indholdsfortegnelse
  • Sidefod
  • Dansk da
Scientific article 18. DEC 2024
  • Health Care
  • Economy and Governance
  • Health Care, Economy and Governance

Risk-based pricing models and the role they might play in patients’ access to new stem cell therapies

Authors:

  • Klaus Hoeyer
  • Anne Sofie Borsch
  • Kim Bak Jensen
  • Agnete Kirkeby
  • Casper Steenholdt
  • Sarah Wadmann
  • Health Care
  • Economy and Governance
  • Health Care, Economy and Governance
Download
Download
Stem cell research is currently undergoing a promising transformation from primarily basic research to increasing emphasis on translation and clinical trials. To reach patients, however, stem cell treatments need to be not only technically but also economically viable. In this commentry we present insights into emerging pricing models that may help ensure access to advanced and expensive treatments like stem cell therapies. Further, we present some reflections on the practical and ethical challenges that these models involve. We provide this information to allow the field of translational stem cell research to think ahead and to raise awareness of the outstanding social and ethical issues.

Authors

  • Klaus HoeyerAnne Sofie BorschKim Bak JensenAgnete KirkebyCasper SteenholdtSarah Wadmann

About this publication

  • Published in

    Regenerative Medicine
VIVE – The Danish Centre for Social Science Research provides knowledge that contributes to developing the welfare society and strengthening quality development, efficiency enhancement and governance in the public sector, both in municipalities, regions and nationally.
Tel: +45 44 45 55 00
E-mail: vive@vive.dk
EAN: 5798000354845
CVR: 23 15 51 17